NEW YORK (TheStreet) -- Seres Therapeutics (MCRB) - Get Report shares closed trading down 25.70% to $38.19 in the second day of trading since the company's upsized initial public offering on Friday.

The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share on Friday before closing trading up 68% to $50.49.

The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.

Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.

The drug candidate is currently in Phase II trials.

Image placeholder title

MCRB Price

data by